Telix Expands Lutetium-177 based therapeutic products Network through Clinical Supply Agreement with Eckert & Ziegler and Shine Technologies

Telix Pharmaceuticals Limited (Telix, Australia) is engaged in molecularly targeted radiation (MTR) investigational products labeled with lutetium-177 (¹⁷⁷Lu), a therapeutic isotope. Telix has an existing ¹⁷⁷Lu supplier network, which includes a commercial supply agreement with ITM Isotope Technologies Munich SE, and clinical supply agreements with the Australian Nuclear Science and Technology Organisation (ANSTO), and Eczacıbaşı-Monrol (Monrol). As Telix advances its late-stage clinical trials using ¹⁷⁷Lu, it is building a global supplier network with proximity to major international markets, capable of consistently delivering high-quality, no-carrier-added ¹⁷⁷Lu to patients.

Enhancing it’s ¹⁷⁷Lu supply, Telix recently announced  global clinical supply agreements with Eckert & Ziegler Strahlen- und Medizintechnik AG (EZAG, Berlin, Germany) and with SHINE Technologies, LLC (SHINE, USA), for highly pure no-carrier-added (n.c.a.) lutetium-177 (¹⁷⁷Lu) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.

EZAG as well as SHINE will immediately commence supply of n.c.a. ¹⁷⁷Lu for use in clinical trials of Telix’s therapeutic candidates TLX591 (¹⁷⁷Lu-rosopatamab for advanced prostate cancer) and TLX250 (¹⁷⁷Lu-girentuximab for kidney cancer), with focus on the local markets in Europe and USA respectively.

To read more please visit:

https://www.globenewswire.com/news-release/2022/02/08/2381422/0/en/Telix-Expands-Lutetium-177-Network-with-Eckert-Ziegler-Clinical-Supply-Agreement.html

Source: GlobeNewswire

https://www.shinefusion.com/news/shine-and-telix-pharmaceuticals-announce-lutetium-177-clinical-supply-agreement/

Source: SHINE